CD8A and neoplasm: Injected with an immune adjuvant, poly(I:C), XCL1-OT-I elicited potent CD8+ T-cell responses, and showed more prominent antitumour effects than the OT-I peptide or OVA protein in both, prophylactic and therapeutic tumour models.